---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-253436"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2026-06-02T20:01:14+00:00"
generated_at: "2026-06-02T20:02:13.724870+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences stockholders approve amended equity plan adding 1.85M new shares

## Summary
- Approved A&R 2021 Equity Incentive Plan with 1,850,000 newly requested shares; total reserve 5,190,000.
- Class III directors elected: Steven Kornfeld, Scott Brun, Paul A. Wagner (vote results provided).
- Advisory vote on named executive officer compensation for FY2025 passed (12.1M for, 3.8M against, 1.5M broker non-votes).
- KPMG ratified as independent auditor for FY2026 (17.7M for, 3K against, 40K abstentions).

## SEC filing metadata
- accession: 0001193125-26-253436
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2026-06-02T20:01:14+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312526253436/0001193125-26-253436-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312526253436/d110060d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-253436
- JSON: https://secwatch.observer/filing/0001193125-26-253436.json
- Plain text: https://secwatch.observer/filing/0001193125-26-253436.txt

## Source-grounded claims
- claim_id: 267bbcb3676ca77b7320124cd44fe7e65af33345
  claim: Forte Biosciences, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-05-29 meeting.
  evidence_excerpt: 2. Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 17,722,893 3,182 39,959 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419041/000119312526253436/0001193125-26-253436-index.htm
- claim_id: 9afd29ce8adb36a637b8106d060fdbc3dc9d54b7
  claim: Forte Biosciences, Inc. shareholders approved Approval of the Amended and Restated 2021 Equity Incentive Plan at the 2026-05-29 meeting.
  evidence_excerpt: 4. Approval of the Amended and Restated 2021 Equity Incentive Plan . The Company’s stockholders approved the A&R 2021 Equity Incentive Plan. The votes regarding the proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 11,911,879 3,997,050 351,042 1,506,063
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419041/000119312526253436/0001193125-26-253436-index.htm
- claim_id: f24db8e8aafd02d8330bfb3364a0561aa15924f7
  claim: Forte Biosciences, Inc. shareholders approved Election of Class III Directors at the 2026-05-29 meeting.
  evidence_excerpt: 1. Election of Class III Directors. The following nominees were elected to serve as Class III directors, each to hold office until the Company’s 2029 annual meeting of stockholders or until his respective successor has been duly elected and qualified or his or her earlier resignation or removal: Nominee Votes For Votes Withheld Broker Non-Votes Steven Kornfeld 12,286,043 3,973,928 1,506,063 Scott Brun, M.D. 12,958,889 3,301,082 1,506,063 Paul A. Wagner, Ph.D. 16,027,110 232,861 1,506,063
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419041/000119312526253436/0001193125-26-253436-index.htm
- claim_id: fbca1bb115df24ec530ae8e4818fc9a68d62677a
  claim: Forte Biosciences, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-05-29 meeting.
  evidence_excerpt: 3. Advisory Vote on Executive Compensation. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers for the fiscal year ended December 31, 2025. The votes regarding the proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 12,143,153 3,764,729 352,089 1,506,063
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419041/000119312526253436/0001193125-26-253436-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.